At the time of writing, Quince Therapeutics Inc [QNCX] stock is trading at $1.54, down -4.94%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The QNCX shares have gain 42.59% over the last week, with a monthly amount glided 105.33%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
For the past year, the stock price of Quince Therapeutics Inc fluctuated between $0.51 and $1.79. Quince Therapeutics Inc [NASDAQ: QNCX] shares were valued at $1.54 at the most recent close of the market.
Analyzing the QNCX fundamentals
Gross Profit Margin for this corporation currently stands at -9.78% with Operating Profit Margin at -818.11%, Pretax Profit Margin comes in at -1472.36%, and Net Profit Margin reading is -1475.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.73 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4000 points at the first support level, and at 1.2600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7000, and for the 2nd resistance point, it is at 1.8600.
Ratios To Look Out For
It is important to note that Quince Therapeutics Inc [NASDAQ:QNCX] has a current ratio of 6.15. Also, the Quick Ratio is 6.15, while the Cash Ratio stands at 0.76.
Transactions by insiders
Recent insider trading involved Thye Dirk, CEO AND CHIEF MEDICAL OFFICER, that happened on Aug 30 ’24 when 77000.0 shares were purchased. CEO AND CHIEF MEDICAL OFFICER, Thye Dirk completed a deal on Aug 29 ’24 to buy 77500.0 shares. Meanwhile, PRESIDENT Ryan Charles S. bought 48387.0 shares on Aug 20 ’24.
